Can a single Immune-Targeting drug quiet an autoimmune kidney disease?

NCT ID NCT05914155

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests whether rituximab, an infusion drug that calms certain immune cells, can help people with idiopathic membranous nephropathy and nephrotic syndrome. Participants receive either rituximab or a placebo, and the study tracks how many achieve a significant reduction in urine protein, a key sign of kidney improvement. The goal is to see if this treatment can offer a safer, steroid-free way to manage the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
rituximab (an infusion drug that targets certain immune cells)
What this could lead to
If successful, rituximab could become a steroid-free option to help people with this kidney disease achieve remission and avoid progression to kidney failure.
What could go wrong
This is a phase 3 trial, but results are not guaranteed. Rituximab can have side effects like infusion reactions and increased infection risk, and not all patients may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLOMERULONEPHRITIS, MEMBRANOUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Anjo Kosei Hospital

    Anjo, Aichi-ken, 4468602, Japan

  • Asahikawa Medical University Hospital

    Asahikawa, Hokkaido, 0788510, Japan

  • Fujita Health University hospital

    Toyoake, Aichi-ken, 4701192, Japan

  • Hamamatsu University Hosptial

    Hamamatsu, Shizuoka, 4313129, Japan

  • Juntendo University Urayasu Hospital

    Urayasu, Chiba, 2790021, Japan

  • Kanazawa University Hospital

    Kanazawa, Ishikawa-ken, 9208641, Japan

  • Kasugai Municipal Hospital

    Kasugai, Aichi-ken, 486-8510, Japan

  • Konan Kosei Hospital

    Kōnan, Aichi-ken, 4838704, Japan

  • Kumamoto University Hospital

    Kumamoto, Kumamoto, 8608556, Japan

  • Kurume University Hospial

    Kurume, Fukuoka, 8300011, Japan

  • Kyoto University Hospital

    Kyoto, Kyoto, 6068507, Japan

  • Kyushu University Hospital

    Fukuoka, Fukuoka, 8128582, Japan

  • Mie University Hospial

    Tsu, Mie-ken, 5148507, Japan

  • Nagoya University Hospital

    Nagoya, Aichi-ken, 4668560, Japan

  • Osaka University Hospital

    Osaka, Osaka, 5650871, Japan

  • Tazuke Kofukai, Medical Research Institute, Kitano Hospital

    Osaka, Osaka, 5308480, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, 9808574, Japan

  • University Hospital,Kyoto Prefectural University of Medicine

    Kyoto, Kyoto, 6028566, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.